Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAINBIRD: Bemarituzumab + Ramucirumab + Paclitaxel in FGFR2b-positive Advanced Gastric or GEJ Cancer
jRCT2031240547Phase 2Suspended
- Sponsor
- Amgen
- Start
- Apr 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bemarituzumab in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma, sponsored by Amgen. Primary endpoint: Objective response rate (central assessment). Started Apr 2025; status: suspended.
02
Drugs
bemarituzumab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on jRCT2031240547.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240547.